GLP-1
‘Possible’ GLP-1 effects in substance use disorders
Despite “lots of interest” in possible reductions in alcohol and smoking, cost and side effects may present barriers to using popular weight loss drugs in addiction medicine Major studies have …
What could expanding GLP-1 access on PBS look like?
Four-in-10 Australian adults may be eligible to use GLP-1 RA treatment for chronic weight management, a study has found Nearly eight million Australian adults were eligible for glucagon-like peptide-1 receptor …
Price must be right to list GLP-1s
Government committed to working with industry stakeholders and patients to support safe and sustainable access to medicines through the PBS, Minister says An agreement on pricing is needed before glucagon-like peptide-1 (GLP-1) …
World news wrapup – 7 May 2026
Big four consultancy firm announces plans to drop funding for GLP-1s for staff, unless they have diabetes; push for increased dispensing fees as German pharmacies go out of business; North …
Research Roundup
Debbie Rigby rounds up the latest research news GLP-1 Receptor/Dual Agonists for Weight Loss A systematic review and network meta-analysis of 127 RCTs concluded that tirzepatide and semaglutide are most …
Wholesaler forecasts multi-year growth for GLP-1s
Glucagon-like peptide-1 medications are already delivering significant growth for wholesalers, but the best is yet to come, Symbion’s chief executive says Uptake of glucagon-like peptide-1 (GLP-1) products in Australia is on track for significant …
Consumer focus on health to benefit pharmacy: Macquarie
GLP-1s and front-of-shop health and beauty to drive growth in the Australian pharmacy market Community pharmacies are set to benefit from consumers’ focus on health in the post-Covid-19 environment, analysts …